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Background: Chronic hepatitis C virus (HCV) may progress to advanced liver disease (ALD), including
decompensated cirrhosis and/or hepatocellular carcinoma (HCC). ALD can lead to significant clinical and economic
consequences, including liver transplantation. This study evaluated the health care costs associated with ALD
among HCV infected patients in a Medicaid population.
Methods: Using Florida Medicaid claims data, cases were patients with at least 1 diagnosis of HCV or prescription
therapy for HCV (ribavirin plus interferon, peginterferon, or interferon alfacon-1) prior to an incident ALD-related
diagnosis (“index event”) between 1999 and 2007. ALD-related conditions included decompensated cirrhosis, HCC,
or liver transplant. A cohort of HCV patients without ALD (comparison group subjects) were matched 1-to-1 based
on age, sex, and race. Baseline and follow-up were the 12 months prior to and following index, respectively; with
both periods allowing for a maximum one month gap in eligibility. For both case and comparison patient cohorts,
per-patient-per-eligible month (PPPM) costs were calculated as total Medicaid paid amount for each patient over
their observed number of eligible months in follow-up, divided by the patient’s total number of eligible months. A
generalized linear model (GLM) was constructed controlling for age, race, Charlson score, alcoholic cirrhosis, and
hepatitis B to explore all-cause PPPM costs between study groups. The final study group included 1,193 cases and
matched comparison patients (mean age: 49 years; 45% female; 54% white, 23% black, 23% other).
Results: The majority of ALD-related diagnoses were for decompensated cirrhosis (92%), followed by HCC (6%) and
liver transplant (2%). Cases had greater comorbidity (mean Charlson score: 3.1 vs. 2.3, P < 0.001). All-cause inpatient
use up to 1-year following incident ALD diagnosis was significantly greater among cases with ALD (74% vs. 27%,
P < 0.001). In the GLM, cases had 2.39 times greater total adjusted mean all-cause PPPM costs compared to the
comparison group ($4,956 vs. $1,735 respectively; P < 0.001). Among cases, mean total unadjusted ALD-related costs
were $1,356 PPPM, which were largely driven by inpatient costs ($1,272).
Conclusions: Our results suggest that among patients diagnosed with HCV, the incremental costs of developing
ALD are substantial, with inpatient stays as the main driver of these increased costs.
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In 2008, the World Health Organization estimated that
between 2.2 and 3.0% of the world’s population was
infected with the hepatitis C virus (HCV), or approxi-
mately 130–170 million individuals [1]. In the United
States, it is estimated that approximately 1.3% of the popu-
lation is infected [2]. The majority of infections occurred
over 20 years ago with the peak incidence of acute HCV
infections estimated at 291,000 cases in 1989 and drop-
ping to approximately 18,000 incident cases in 2008 [3].
This marked decrease in incidence is in part due to
improved blood donor screening and safer injection drug
practices. As most patients were infected two decades ago,
there is a relatively low prevalence of HCV infection
among patients younger than age 45 compared to older
age groups, with peak prevalence in the US occurring
among patients aged 40–49 years of age in 2010 [2].
The economic burden of HCV is substantial with an-
nual total all-cause health care costs estimated between
$9,576 and $22,424 (adjusted to 2009 dollars) [4-7] and
HCV-related costs estimated at approximately $7,343 in
the first year following HCV diagnosis (2009 dollars) [5].
The main source of clinical and patient burden stems
from the onset of decompensated cirrhosis and progres-
sion to hepatocellular carcinoma (HCC). As liver disease
caused by HCV progresses slowly, many patients with
HCV remain asymptomatic for years following infection
with the virus [8]. Results from a recent model (ignoring
effects of HCV treatment) showed that as the duration
of HCV infection increases in surviving cohorts today,
the proportion of patients with cirrhosis and other liver
complications, such as hepatic decompensation, HCC,
and liver-related deaths will increase dramatically over
the next 10 years [9]. The same model estimated that
mortality from HCV-related liver disease increased by
150% between the 1990s and 2000s, from a total of
56,377 deaths between 1990–1999 to 145,667 deaths be-
tween 2000 and 2009 [9]. Currently, approximately one-
third of HCC cases in the US are attributed to HCV-
related liver damage and HCV is the leading cause of
liver transplantation [10]. A recent US-based model esti-
mated that as HCV progresses, the proportion of all
HCV patients with cirrhosis would increase from 25% in
2010 to 37% in 2020 [9].
Although the clinical progression to advanced liver
disease (ALD) among patients with HCV is documented,
little is known about the economic burden of ALD in a
Medicaid population. State Medicaid programs covered
approximately 48.6 million persons in 2010, and is
expected to grow substantially when the Patient Protec-
tion and Affordable Care Act is fully enacted over the
next several years [11]. In one modeling study, Wong
et al. projected that direct medical costs in the US of
managing future HCV-related disease (i.e. ALD-relateddiagnoses) could range between $6.5 and $13.6 billion
between the years 2010 and 2019 with substantial add-
itional societal costs attributed to approximately
720,000 years of life lost due to HCV-related decompen-
sated cirrhosis and HCC [12]. Additionally, a 2012 sys-
tematic literature review of the economic burden of
HCV-associated disease concluded that most cost esti-
mates were from 1990, and were in need of updating
given the aging cohort of HCV-infected patients [13].
As the HCV population is aging with a growing pro-
portion of patients developing ALD-related complica-
tions in the coming years [9,14], there is a need for
research on the direct health care cost burden of HCV-
related ALD. The goal of this study was to assess the
resource use and costs associated with ALD among
patients diagnosed with HCV using administrative
claims data from a large state Medicaid program.
Methods
Overview
This retrospective database analysis used administrative
claims and enrollment records from Florida Medicaid
database over the period from July 1, 1998 through June
30, 2008. Study cases were identified based on medical
claims with a diagnosis of HCV or a relevant drug ther-
apy (see below for HCV therapies) with an incident
ALD-related diagnosis; non-ALD matched comparison
group patients were selected to estimate the incremental
burden of ALD. Key study measures included all-cause
and ALD-related resource use and costs by resource use
component including inpatient, outpatient, pharmacy,
and other resource use.
Data source
The Florida Medicaid program covers approximately 3
million low-income or disabled individuals or approxi-
mately 16% of the Florida population in 2008 [15,16].
The Florida Medicaid database consists of 2 patient de-
identified files: (1) a claims file, with a de-identified pa-
tient ID, details on medical and pharmacy utilization, in-
cluding date of service, place of service, International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) codes, procedure codes, physician
specialty, national drug codes, drug quantity dispensed,
days supplied, and Medicaid paid amounts; and (2) an
eligibility file, with de-identified patient ID, details on
monthly enrollment and patient demographics, and date
of death as of the latest year of available claims. No
information on specific causes of death is available.
Patient selection
Cases
Patients were initially identified as eligible cases if they
had at least 1 HCV diagnosis including acute, chronic,
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070.41, 070.51, 070.44, 070.54, 070.70, 070.71, V02.62) in
any of 5 diagnosis fields on an inpatient or outpatient
claim, or prescription therapy indicative of HCV (at least
one claim for ribavirin and at least one additional claim
for either interferon, peginterferon, or interferon
alfacon-1 within the same fiscal year). In addition, cases
were required to have an incident ALD-related diagnosis
or procedure, defined by medical claims for at least 1 of
the following conditions (using ICD-9-CM codes) be-
tween July 1, 1999 and June 30, 2007, and no such diag-
nosis in the prior 12 months:
(1) Decompensated cirrhosis diagnosis: esophageal varices
with/without bleeding (ICD-9-CM codes 456.0x,
456.1x), esophageal varices in diseases classified
elsewhere with/without bleeding (456.20, 456.21),
ascites (789.5x), hepatic coma/encephalopathy or
unspecified encephalopathy (572.2x, 348.3x),
hepatorenal syndrome (572.3x), portal hypertension
(572.4x);
(2) HCC (155.0x); or
(3) Liver transplant procedure (50.51, 50.59; or CPT-4
codes 47135, 47136), or history of liver transplant
diagnosis (V42.7).
The date of the first ALD-related diagnosis was termed
the “index date” with the baseline period defined as the
12 months prior to the index date and the follow-up
period defined as the 12 months following index (includ-
ing the index date). Patients were allowed a maximum one
month gap in Medicaid eligibility in the baseline and/or
follow-up periods. Moreover, patients who died had their
follow-up end as of the date of death. An HCV diagnosis
was required in the baseline period prior to the first ALD-
related diagnosis. If patients had more than 1 ALD-related
diagnosis on their index date the following hierarchy was
applied to create 3 mutually exclusive groups: liver trans-
plant diagnosis or procedure code, followed by HCC diag-
nosis and decompensated cirrhosis diagnosis. If patients
were enrolled in Medicare or a Health Maintenance
Organization (HMO) at any time during the study period
they were excluded from analyses since complete claims
may not be available for them.
Comparison cases
A comparison group was matched 1-to-1 with cases
based on 5-year age groups, sex, and race after they met
the eligibility criteria: had at least 1 inpatient or out-
patient diagnosis of HCV in any of 5 diagnosis fields on
an inpatient or outpatient claim, or prescription therapy
indicative of HCV; had no diagnosis of ALD in the base-
line or follow-up period; was not enrolled in Medicare
or an HMO at any time during the study period; andhad continuous Medicaid eligibility in the entire baseline
and follow-up periods (including an allowed maximum
one month gap in Medicaid eligibility) or until death,
whichever occurred first. Each eligible comparison pa-
tient was assigned the same index date as his/her
matched case.
Study measures
Study measures included baseline demographic and
clinical characteristics, selected outcomes, and resource
use and cost measures evaluated over the follow-up
period. Patients’ age was assessed at the index date and
Charlson comorbidities were assessed in the baseline
period. The Deyo-Charlson comorbidity score is a meas-
ure of physical health status commonly used in studies
of medical claims and chronic disease [17-19]. This
score is calculated by assigning points to presence of the
following 17 conditions (with higher scores indicating
poorer overall health status): myocardial infarction, con-
gestive heart failure, peripheral vascular disease, cerebro-
vascular disease, dementia, COPD, rheumatologic
disease, peptic ulcer disease, mild liver disease, diabetes
mellitus (uncomplicated), diabetes with chronic compli-
cations, hemiplegia or paraplegia, renal disease, any ma-
lignancy, liver disease, metastatic solid tumor, and AIDS.
In this analysis, we excluded “liver disease” from the
Charlson score calculation as this was a selection criter-
ion for our “case” cohort.
Prevalence of other ALD and non-ALD related
selected diagnoses (using ICD-9-CM codes) evaluated in
the follow-up period including: alcoholic cirrhosis
(571.1x), diabetes without chronic complications (250.0x-
250.3x, 250.7x), gastrointestinal bleeding (578.xx, 530.82),
hepatitis B virus (HBV) (070.2x, 070.3x), human immuno-
deficiency virus (042.xx), other sequelae of chronic liver
disease (572.8x), acute renal failure (584.5x-584.9x), and
unspecified disorder of the liver (573.9x). Prevalence of
selected ALD-related diagnoses in follow-up were also
reported (if their prevalence was >5%). Mortality was also
assessed for both the case and comparison cohorts over
follow-up. Both all-cause and ALD-related resource use
and costs (defined as the Medicaid paid amount) were
assessed in the follow-up period, including hospitaliza-
tions and hospital days, outpatient services, pharmacy pre-
scriptions (analyzed for all-cause resource use and costs
only), and other resource use (including nursing home
stays, home health, hospice, and other services). ALD-
related costs included any payments from claims with a
primary or secondary ALD-related diagnosis or procedure,
as listed above.
Data analyses
Descriptive analyses of all study measures were per-
formed. All-cause resource utilization and costs were
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cohorts, while ALD-related resource use and costs were
reported for cases only, stratified by index ALD type.
This only included decompensated cirrhosis or HCC
since the transplant group included only 21 patients of
whom only one underwent an actual transplant proced-
ure during the study period. Differences between cases
and comparison group patients were tested for statistical
significance (defined as P < 0.05) with t-tests used to
evaluate the statistical significance of differences in con-
tinuous variables with approximately normal distribu-
tions, nonparametric rank-order Wilcoxon tests for
continuous variables with skewed distributions, and
Cochran-Mantel-Haenszel or Fisher’s exact tests used
for comparisons of proportions. Resource use during
follow-up was reported as the percentage of patients
with use in each category of interest and mean units of
resource use (e.g., hospital admissions, hospital days)
were reported on a per-patient-per-eligible month
(PPPM) basis.
Costs were defined as the Medicaid paid amount over
follow-up, inflation-adjusted using the medical care
component of the consumer price index to 2009 dollars.
For both case and comparison group cohorts, PPPM
costs were calculated as total Medicaid paid amount for
each individual patient over their entire number of eli-
gible months in follow-up, divided by the patient’s total
number of eligible months, with summary statistics
(mean, standard deviation, range) calculated for the en-
tire cohort. A generalized linear model using a log-link
function and negative binomial distribution was used to
adjust total all-cause costs for potential confounding fac-
tors including age, race, Charlson score, comorbid alco-
holic cirrhosis, and HBV. This model functional form
was chosen since our cost data were significantly right-
skewed). SAS software (Version 9.0, SAS Institute, Cary,
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Demographic and clinical characteristics
There were 34,542 patients identified with a diagnosis or
prescription therapy indicative of HCV, of whom 8,533
had a diagnosis of both HCV and ALD, and 26,009 had
a diagnosis of HCV alone. After applying all selection
criteria 1,193 cases and 1,193 matched comparison
group patients were available for analysis (Figure 1). The
population was predominantly male (54.6%), and
middle-aged (mean age 49 years), with just over half of
patients identifying their race/ethnicity as White (54.1%)
(Table 1). The baseline mean ± SD Charlson score (ex-
cluding HCC, mild liver disease, and liver disease) was
significantly higher among cases (3.1 ± 3.2) than com-
parison group patients (2.3 ± 2.7) (P < .001), with the
most common Charlson comorbidities among cases
being chronic pulmonary disease (34.0%), diabetes
(25.4%), and acquired immune deficiency syndrome
(24.6%). Approximately one-third of cases (35.1%) and
less than 1% of comparison group patients died during a
mean (±SD) follow-up of 277 ± 135 days among cases
and 366 ± 8 days among comparison group patients
(Table 1).
Among cases, nearly all had decompensated cirrhosis
as the index ALD-related claim (N = 1,098; 92.0%), fol-
lowed by HCC (N = 73; 6.1%) or liver transplant (N = 22;
1.8%) claims. Four patients had both a decompensated
cirrhosis and HCC claim on their index date and were
thus considered to have HCC as their index ALD-related
diagnosis. Among patients who were initially diagnosed
with decompensated cirrhosis or HCC diagnosis at
index, 3.1% and 6.8% received a liver transplant in fol-
low-up, respectively. The most common ALD-related
diagnoses among cases in follow-up were ascites (54.5%)
and alcoholic cirrhosis (28.8%). Additionally, HIV
(25.2%) and diabetes (24.8%) were prevalent diagnoses in
follow-up (Table 1).N= 34,542
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Male (%) 54.6% 54.6% 1.000
Race
White 54.1% 54.1% 1.000
Black 23.3% 23.3% 1.000
Hispanic 9.8% 9.8% 1.000
Other 12.8% 12.8% 1.000
Charlson score1




Duration of follow-up (days)




Died during evaluation period (%) 35.1% 0.8% < .001
Selected non-ALD-related
diagnoses (%)
Alcoholic cirrhosis 28.8% 1.1% < .001
Diabetes 24.8% 19.8% 0.004
Gastrointestinal bleeding 20.2% 3.6% < .001
HBV 9.7% 2.9% < .001
HIV 25.2% 23.7% 0.418
Other sequelae of chronic liver
disease
10.5% 0.3% < .001
Acute Renal failure 13.1% 2.2% < .001
Unspecified disorder of the liver 11.2% 1.8% < .001
Selected ALD-related
diagnoses (%)
Ascites 54.5% 0.0% < .001
Esophageal varices without
bleeding
11.2% 0.0% < .001
Table 1 Baseline and follow-up demographic, clinical, and
survival characteristics (Continued)
Hepatic coma (encephalopathy) 19.4% 0.0% < .001
Portal hypertension 11.7% 0.0% < .001
Source: Florida Medicaid database: claims with dates of service between July
1, 1998 and June 30, 2008.
Note: Comparison patients were matched based on 5-year age groupings, sex,
and race to cases.
1T-tests were used to evaluate differences in mean age and Charlson score,
while Wilcoxon tests were used for duration of follow-up. The Fisher Exact 2-
tailed test was used for comparisons of proportions.
2Race/ethnicity was patient-identified; with "Other" race/ethnicity including
American Indian, Asian, and others.
3Charlson score excludes HCC, 'Mild Liver Disease' and 'Liver Disease'
comorbidities.
4Significance testing was not performed on ALD-related diagnoses as the
comparison cohort could not have any of these diagnoses in baseline or
follow-up by definition. These diagnoses were based on all inpatient and
outpatient diagnoses observed over the follow-up period: ALD advanced liver
disease, HBV hepatitis B virus, HCV hepatitis C virus, HIV human
immunodeficiency virus.
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A significantly higher proportion of cases than compari-
son group patients had at least 1 all-cause inpatient
hospitalization (73.6% vs. 27.1%), outpatient service use
(99.2% vs. 96.1%), or other resource use (91.3% vs.
88.4%) in the follow-up period (all P < .001, except other
resource use P = .025) (Table 2). The mean number of
hospital admissions PPPM was significantly higher
among cases than comparison group patients (0.3 vs.
0.1, P < .001), as were the mean number of hospital days
PPPM (1.9 vs. 0.3, P < .001). Additionally, cases had 15.4
more outpatient claims PPPM compared to comparison
group patients (19.4 vs 4.1; P < .001).
Among cases, nearly half had an ALD-related inpatient
hospitalization in one year of follow-up (43.8%), 89.0% had
ALD-related outpatient service use, and 5.5% had ALD-
related other service use (Table 3). Patients with a decom-
pensated cirrhosis diagnosis on their index date were more
likely to have ALD-related inpatient hospitalizations
(45.0% vs. 37.0%) or ALD-related outpatient service use in
follow-up (90.4% vs. 87.7%) versus those with an HCC
diagnosis at index, although these differences were not
statistically significant. Conversely, cases with an HCC
claim at index had a significantly greater percentage with
“other” service use (including nursing home, home health,
hospice, and other services) during follow-up versus those
with a decompensated cirrhosis claim (26.0% vs 4.2%,
P < .001). The number of hospital admissions on a PPPM
basis was similar for those with decompensated cirrhosis
versus HCC as the index ALD type (0.1 vs 0.2 admissions
PPPM, P = .445), as were mean number of hospital days
(0.9 vs 1.4 days, P = 0.592).
All-cause and ALD-related medical costs
The total unadjusted all-cause medical costs were esti-
mated at $37,424 among cases and $20,762 among
Table 2 All-cause health care resource use among patients with HCV and ALD (cases) and matched patients with HCV
and no ALD (comparison)
Patients with HCV
and ALD (Cases)





Percent with ≥1 hospitalization (1 yr follow-up) 73.6% 27.1% 46.5% < .001
Hospital admissions (PPPM) < .001
Mean 0.3 0.1 0.3
SD 0.4 0.1
Median 0.2 0.0
Hospital days (PPPM) < .001




Percent with ≥1 outpatient service (1 yr follow-up) 99.2% 96.1% 3.1% < .001
Outpatient office/clinic services (PPPM) < .001




Percent with ≥1 medication dispensed (1 yr follow-up) 89.8% 92.0% −2.2% 0.064
Medications dispensed (PPPM) 0.010




Percent with at least 1 other resource use claim 91.3% 88.4% 2.9% 0.025
Source: Florida Medicaid database: claims with dates of service between July 1, 1998 and June 30, 2008.
Notes: Percentages are those with the resource use of interest at any time during the year.
1 Calculated with the Fisher Exact 2-tailed test used for comparison of proportions, and the Wilcoxon test for comparison of means.
2 Patients may have received multiple outpatient services on the same day, including hospital outpatient, physician, nurse practitioner, physician assistant, clinic,
or other outpatient services.
3 "Other" services include nursing home, home health, hospice, and other services.
ALD advanced liver disease, HCV hepatitis C virus, PPPM per-patient-per-month.
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accounting for months of eligibility). Consistent with re-
source use findings, patients with HCV and ALD had
significantly higher unadjusted inpatient, outpatient, and
other costs versus patients with HCV and no ALD (all
P < .001). The total incremental unadjusted PPPM cost
of ALD among patients with HCV averaged $3,207,
comprised of $2,312 in incremental inpatient costs, $498
in incremental outpatient service costs, and an add-
itional $424 in other costs (Table 4). In a generalized lin-
ear model with negative binomial distribution that
controlled for age, race, Charlson score, comorbid alco-
holic cirrhosis, and HBV, cases had 2.39 times greater
total adjusted mean all-cause PPPM costs compared to
comparison group patients (Table 5) ($4,956 vs. $1,735respectively; P < 0.001), which is slightly lower than our
unadjusted estimate (2.85 or $4,937 / $1,730). Total
ALD-related costs among cases averaged $1,356 PPPM,
with patients having HCC as an index ALD diagnosis
exhibiting greater costs versus those with decompen-
sated cirrhosis as the index ALD diagnosis ($2,297 vs.
$1,319, P = 0.807) (Table 6).
Discussion
In this study using data from the Florida Medicaid pro-
gram, the fourth-largest Medicaid program in the United
States, we found that patients with HCV with an incident
ALD-related diagnosis (cases) had significantly greater all-
cause resource use and costs compared to patients with
HCV without an ALD diagnosis (comparison patients).
Table 3 ALD-related health care resource use among patients with HCV and ALD (cases), by ALD type at index
diagnosis
Variables Index diagnosis
Overall1 Decompensated cirrhosis Hepatocellular carcinoma P-value2
N 1193 1098 73
Inpatient
Percent with a hospitalization (1 yr follow-up) 43.8% 45.0% 37.0% 0.224
Hospital admissions (PPPM)
Mean 0.1 0.1 0.2 0.445
SD 0.3 0.3 0.3
Median 0.0 0.0 0.0
Hospital days (PPPM)
Mean 0.9 0.9 1.4 0.592
SD 2.1 2.0 3.2
Median 0.0 0.0 0.0
Outpatient Services3
Percent with an outpatient service (1 yr follow-up) 89.0% 90.4% 87.7% 0.416
Outpatient office/clinic services (PPPM)
Mean 1.8 1.7 4.8 0.251
SD 5.9 5.0 13.4
Median 0.3 0.3 0.3
Other Services4
Percent with other resource use (1 yr follow-up) 5.5% 4.2% 26.0% <.001
Source: Florida Medicaid database: claims with dates of service between July 1, 1998 and June 30, 2008.
Notes: Percentages are those with the resource use of interest at any time during the year. ALD-related resource use includes all claims with an ALD-related code.
1 “Overall” includes 22 patients with an index event defined by either a liver transplant procedure or a diagnosis code indicating history of a liver transplant.
2Calculated with the Fisher Exact 2-tailed test used for comparison of proportions, and the Wilcoxon test for comparison of means.
3Patients may have received multiple outpatient services on the same day, including hospital outpatient, physician, nurse practitioner, physician assistant, clinic, or
other outpatient services.
4 "Other" services include nursing home, home health, hospice, and other services.
ALD advanced liver disease, HCV hepatitis C virus, PPPM per-patient-per-month.
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lowing the first ALD-related diagnosis among cases were
estimated at $4,956, while mean total PPPM costs for
comparison patients were estimated at $1,735. A substan-
tially larger proportion of all-cause costs were comprised
of inpatient hospitalizations among cases (54%) vs. con-
trols (19%). Total ALD-related costs in the year following
an incident ALD-related diagnosis among patients with
both HCV and ALD averaged $1,356 PPPM, or approxi-
mately 27% of all-cause costs in this cohort. These
increased costs among patients with HCV and ALD may
be linked to the observed higher use of healthcare
resources in this cohort as shown in these analyses.
There are limited data on the incremental cost burden
of ALD among Medicaid patients with HCV. Past re-
search has focused primarily on the burden of HCV in
general, not specific to patients with and without ALD-
related diagnoses. Additionally, prior research has fo-
cused on patients covered by commercial health plans
[4-7,20], which may be different than those covered by a
state Medicaid program. Despite these differences,previous studies showed that annual health care costs
among patients with HCV ranged from $9,576 to
$22,424 (adjusted to 2009 USD) [4-7], which is similar
to the all-cause estimate among our comparison group
of patients with HCV and no ALD ($20,762). In an ana-
lysis of patients with an incident diagnosis of chronic
HCV who were enrolled in a managed care organization
(MCO), the annual all-cause costs in the first year fol-
lowing diagnosis were estimated at $22,424 for patients
with HCV and $5,831 for patients without HCV (incre-
mental $16,593; adjusted to 2009 USD) [5]. In a similar
analysis of private MCO data, Poret et al. estimated total
all-cause average payments in the year following the first
HCV diagnosis at approximately $17,491 versus $3,020
in a comparison cohort with no HCV (adjusted to 2009
USD) [6]. Armstrong and colleagues reported total an-
nual all-cause costs among patients with HCV who were
treated with interferon alfa plus ribavirin therapy and
enrolled in a large MCO to be approximately $9,577
(adjusted to 2009 USD) [4]. Of the total all-cause costs
among treated patients with HCV, approximately $8,929
Table 4 All-cause PPPM healthcare costs among Medicaid
beneficiaries with HCV and ALD (cases) and matched


























Mean (SD) $4,937 ($5,236) $1,730 ($2,309) $3,207 < .001
Median $3,146 $1,002
Source: Florida Medicaid database: claims with dates of service between July
1, 1998 and June 30, 2008.
Notes: All costs are inflated to 2009 USD using the Medical Care component of
the CPI. Costs over the entire follow-up period were divided by the number of
eligible patient months to create the PPPM cost estimates.
1Calculated with the Wilcoxon test for comparison of means.
2Patients may have received multiple outpatient services on the same day,
including hospital outpatient, physician, nurse practitioner, physician assistant,
clinic, or other outpatient services.
3 "Other" costs include nursing home, home health, hospice, and other services.
ALD advanced liver disease, HCV hepatitis C virus, PPPM per-patient-per-month.
Table 5 Generalized linear model1 predicting adjusted
all-cause PPPM healthcare costs
Parameter Beta-coefficient Odds ratio P-Value
Male 0.0508 1.05 0.266
Charlson Score2 of 1 0.2977 1.35 <.001
Charlson Score of 2 0.4745 1.61 <.001
Charlson Score ≥3 0.8231 2.28 <.001
Alcoholic Cirrhosis 0.2759 1.32 <.001
Hepatitis B Virus (HBV) 0.3638 1.44 <.001
Age (Continuous Variable) −0.0048 1.00 0.061
Black 0.1557 1.17 0.007
Hispanic −0.1095 0.90 0.169
Other Race 0.0869 1.09 0.219
Cases (HCV with ALD) 0.8728 2.39 <.001
Source: Florida Medicaid database: claims with dates of service between July
1, 1998 and June 30, 2008.
Reference groups included: Females, Charlson score 0, patients with no
diagnosis of alcoholic cirrhosis or HBV, Whites, and comparison patients (HCV
with no ALD).
Model fit statistics: Degrees of freedom (2374), scaled deviance (2842), log-
likelihood (61454257).
1 Constructed using a using a log-link function and negative binomial distribution.
2 Charlson score excludes HCC, 'Mild Liver Disease' and 'Liver Disease' comorbidities.
PPPM per-patient-per-month.
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other analysis of MCO data, this one among patients
with HCV aged less than age 65, Rosenberg et al. found
total all-cause 3-year costs of $63,055 (annualized ap-
proximately $21,018; adjusted to 2009 USD) [7]. Finally,
in a recent retrospective database analysis of administra-
tive claims data from a large MCO the annualized total
mean all-cause healthcare charges (not costs) per patient
per year (PPPY) were higher for patients with diagnosis
of HCV and ALD (decompensated cirrhosis: $27,000;
HCC: $58,529; liver transplant: $113,116) compared to
patients with HCV and no advanced liver disease
($14,917) (all in 2009 USD) [20]. These results are simi-
lar to our findings of higher costs among patients with
HCV and ALD compared to HCV alone particularly
among patients with diagnosis of HCC or receipt of a
liver transplant, although data on charges are notdirectly comparable to the Medicaid expenditure infor-
mation reported in our paper.
Although the incidence of HCV has declined substan-
tially in the last decade, mortality due to liver-related
complications is projected to increase over the next
25 years due to the aging of the prevalent HCV popula-
tion. As the population ages, more patients will progress
to development of decompensated cirrhosis or HCC.
Increased ALD-related mortality and rates of progres-
sion will lead to a significant economic burden among
the HCV-infected population. In one model-based esti-
mate of the effect of treatment on HCV progression and
liver-related mortality, increasing treatment rates among
patients diagnosed with HCV from approximately 25%
to 50% was projected to decrease the percentage of
patients developing liver failure by 39%, HCC by 30%,
and decrease the number of liver-related deaths by 34%
between 2010 and 2019 [9].
The mortality rate observed among patients with diag-
nosis of HCV and ALD in this study was 35.1% over a
mean of 277 days of follow-up. This estimate is in line
with mortality rates reported in a systematic literature
review of patients with cirrhosis [21]. Patients with stage
3 decompensated cirrhosis (i.e., patients with ascites and
varices) were found to have a one-year mortality rate of
20% while those with stage 4 decompensated cirrhosis
(i.e., those with GI bleeding with or without ascites) had a
mortality rate of 57% at one year. Since over 90% of our
patients with ALD had a diagnosis of decompensated
Table 6 ALD-related PPPM healthcare costs among Medicaid beneficiaries with HCV and ALD (cases), by ALD type at
index ALD diagnosis
Index diagnosis
Variables All ALD-related costs1 Decompensated cirrhosis Hepatocellular carcinoma P-value2
N 1193 1098 73
Inpatient
Mean (SD) $1,272 ($2,926) $1,242 ($2,806) $2,093 ($4,539) 0.624
Median $0 $0 $0
IQR $0-$1,006 $0-$1,056 $0-$1,155
Outpatient
Mean (SD) $83 ($184) $76 ($168) $202 ($341) 0.051
Median $23 $23 $37
IQR $6-$79 $7-$78 $8-$157
Other costs3
Mean (SD) $1 ($11) $1 ($11) $2 ($10) <.001
Median $0 $0 $0
IQR $0-$0 $0-$0 $0-$0
Total costs4
Mean (SD) $1,356 ($2,981) $1,319 ($2,848) $2,297 ($4,700) 0.807
Median $88 $96 $67
Source: Florida Medicaid database: claims with dates of service between July 1, 1998 and June 30, 2008.
Notes: All costs are inflated to 2009 USD using the Medical Care component of the CPI. Costs over the entire follow-up period were divided by the number of
eligible patient months to create the PPPM cost estimates.
1 “ALD-Related Costs” includes all patients with HCV and ALD, including 22 patients whose index ALD diagnosis was a transplant procedure or history of transplant.
2 Calculated with the Wilcoxon test for comparison of means.
3 "Other" costs include nursing home, home health, hospice, and other services.
4 "Total costs" include inpatient, outpatient, pharmacy, and other (nursing home, home health, hospice, and other services) costs. Pharmacy and other costs
comprised < $5 of mean total ALD-related costs in each cohort.
ALD advanced liver disease, HCV hepatitis C virus, PPPM per-patient-per-month.
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3 and 4 cirrhosis patients examined in the review.
Limitations
This study is subject to certain limitations that are com-
mon to all studies that rely on retrospective claims data,
such as potential coding errors and incomplete data [22].
Our estimates of ALD-related resource use and costs may
be slight overestimates, as we defined a claim with any
ALD-related diagnosis (primary or secondary diagnosis) as
disease-related, which may have in some cases captured
nondisease related costs. Additionally, descriptive data also
showed patients with HCV and ALD to have higher preva-
lence of other non-liver related comorbidities, therefore
also potentially causing the incremental cost of ALD to be
an overestimate. Although we controlled for both alco-
holic cirrhosis and hepatitis B, two important comorbid
conditions not included in the Charlson score, we cannot
rule our residual confounding that could have led to an
overestimate of excess costs. Finally, the difference in
pharmacy costs observed (higher pharmacy costs among
controls) may have skewed differences in total all cause
costs between cases and controls due to a higherprevalence of contraindications to interferon-based treat-
ment among patients with HCV and ALD. However, many
of these patients were living with HCV for a number of
years prior to the first year of our data (1998), and already
presumably completed their course of treatment, thus not
overly influencing pharmacy costs. However, we do ac-
knowledge that the prevalence of treatment is likely higher
in the control group and therefore influencing the signifi-
cant difference in pharmacy costs observed in our dataset.
The main decrease in sample size in our study was
due to the requirement that patients be Medicaid-only
eligible with no HMO or Medicare coverage. Therefore,
although this study was conducted using a large state
Medicaid program, costs may not be generalizable to
other Medicaid programs or to other payers. Addition-
ally, exclusion of patients who are dually eligible for Me-
dicaid and Medicare may bias cost estimates downward
as Medicaid patients with Medicare are likely to be
sicker than other patients [23].
Conclusion
This retrospective database analysis showed a substantial
incremental burden of ALD among patients with HCV
Menzin et al. BMC Health Services Research 2012, 12:459 Page 10 of 10
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both HCV and ALD had an average of approximately
$3,200 more in all-cause medical costs on PPPM basis
compared to those with an HCV diagnosis alone. To our
knowledge, this study is the first publication to assess
the incremental cost of ALD among patients with HCV
in a Medicaid population. There is a need for further re-
search in this area, potentially among different patient
populations (e.g. privately insured patients) or subpopu-
lations (e.g., in HCV patients with limited access to
treatment, patients co-infected with human immuno-
deficiency virus and/or hepatitis B virus). Additionally,
studies of lifetime costs among patients with HCV pro-
gressing to ALD would be informative.
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